Gapping up -
With US futures up over 4%, most stocks are trading higher. The following represents stocks with specific catalysts.
In reaction to strong earnings/guidance:
- QIWI +7.2%, LX +6%
Select ETFs showing strength:
- GDX +12.7%, IGV +7.3%, XLI +5.1%, XLE +4.8%, XLK +4.8%, DIA +4.5%, XLF +4.4%, SPY +4.4%, WWW +4.3%, IWM +4.3%, GLD +3.9%
Other news:
- NVAX +45% (achieves all primary endpoints in phase 3 clinical trial)
- CTMX +37% (CytomX Therapeutics and Astellas announce strategic collaboration to develop Probody T-Cell engaging bispecific therapies for treatment of cancer )
- VAPO +23% (has seen significant increase in demand for Vapotherm Precision Flow)
- MMX +17.6% (impacts of the outbreak of COVID-19 as it relates to the Company's royalty and stream interests)
- ARCC +13% (provides COVID-19 update)
- NAT +8.2% (doubles dividend)
- VALE +9.5% (updates on the outbreak of the coronavirus and implications for Malaysia distribution center)
- CCJ +8.7% (temporarily suspends production at Cigar Lake mine)
- ZG +8.1% (withdraws 2020 guidance but expects Q1 to be within or exceed prior guidance)
- JWN +8.1% (announces measures to strengthen financial position)
- PSX +6.9% (announces actions in response to the challenging business environment)
- IRBT +4.4% (withdraws FY20 guidance; guides Q1 revs below consensus)
Analyst comments:
- SPCE +16.8% ( upgraded to Overweight from Equal-Weight at Morgan Stanley)
- TSLA +6.5% (upgraded to Neutral from Sell at UBS)
- INTC +6.4% (upgraded to Outperform from Neutral at Exane BNP Paribas)
- NVDA +6.4% (upgraded to Buy from Hold at Needham)
- KO +6.3% (upgraded to Buy from Hold at HSBC Securities)
- XLNX +5% (upgraded to Buy from Neutral at Goldman)